Anemia prevalence and treatment patterns in chronic kidney disease: a nationwide observational study using a Japanese primary care database (2018–2023)
Clinical and Experimental Nephrology · 2026
DOI: 10.1007/s10157-026-02873-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Experimental Nephrology, 2026. Verfasst von Tetsuhiro Tanaka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Tohoku University Graduate School of Medicine, Miyagi, Japan. Hauptthemen laut MEDLINE: Anemia, Renal Insufficiency, Chronic, Hematinics, Prolyl-Hydroxylase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma, Mitsubishi Tanabe Pharma Corporation, Kyowa Hakko Kirin.
Abstract (Originalsprache)
Background
Anemia in chronic kidney disease (CKD) is associated with poor outcomes, including CKD progression, mortality, and cardiovascular events. Standard treatments include iron supplements and injectable erythropoiesis-stimulating agents (ESAs). Oral hypoxia-inducible factor–prolyl hydroxylase inhibitors (HIF–PHIs) have recently emerged as a new treatment option, providing easier accessibility for general practitioners.
Methods
This real-world descriptive study used the Japan Medical Data Survey database to analyze the prevalence of anemia, anemia treatment, and treatment type in non-dialysis patients with CKD and treated in primary care clinics. Data from 1 January 2018 to 31 December 2023 were assessed and analyzed by subgroups (year, CKD stage, patient age, treatment setting, sex, and region).
Results
This study included 397,419 patients. Anemia treatment rates increased from 16.4% (2018) to 22.7% (2023), accompanied by an increased proportion of patients with hemoglobin levels ≥ 11 g/dL (78.8%–87.9%). From 2020, use of HIF–PHIs increased and use of ESAs decreased, with HIF–PHIs overtaking ESAs in 2022–2023. During 2022–2023 (N = 340,398), patients with more severe CKD stages had lower hemoglobin levels and an increased prevalence of anemia (11.6% [CKD G3a]–73.6% [CKD G5]). Older patients tended to have lower hemoglobin values, increased anemia prevalence, more severe CKD, and increased use of HIF–PHIs and ESAs.
Conclusion
Use of HIF–PHIs in primary care settings in Japan is increasing, resulting in changes to anemia treatment received by patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
- Medical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan.
- Medical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan. toyoshima.kawabata.yk@gmail.com.
Förderung
- Astellas Pharma
- Mitsubishi Tanabe Pharma Corporation
- Kyowa Hakko Kirin
Zitieren
APA
Tanaka, T., Asada, S., Suzuki, K., & Toyoshima, Y. (2026). Anemia prevalence and treatment patterns in chronic kidney disease: a nationwide observational study using a Japanese primary care database (2018–2023). Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-026-02873-2
Vancouver
Tanaka T, Asada S, Suzuki K, Toyoshima Y. Anemia prevalence and treatment patterns in chronic kidney disease: a nationwide observational study using a Japanese primary care database (2018–2023). Clinical and Experimental Nephrology. 2026. doi:10.1007/s10157-026-02873-2
BibTeX
@article{Tanaka2026,
author = {Tanaka, Tetsuhiro and Asada, Shinji and Suzuki, Kohei and Toyoshima, Yuki},
title = {Anemia prevalence and treatment patterns in chronic kidney disease: a nationwide observational study using a Japanese primary care database (2018–2023)},
journal = {Clinical and Experimental Nephrology},
year = {2026},
doi = {10.1007/s10157-026-02873-2}
}
EUVIMED